European authorisation for Zoetis' Poulvac Procerta HVT-ND adds a dual-disease option at the hatchery - and links flock-health design more directly to trade readiness.

In poultry, the economic value of a vaccine is rarely confined to the disease it targets. It also sits in hatchery workflow, flock consistency, veterinary planning and the ability to meet the health expectations of customers and export markets. Zoetis' new European Commission marketing authorisation for Poulvac Procerta HVT-ND is a timely example of that broader equation.

Announced on 7 July, the authorisation covers a live recombinant herpesvirus of turkey vector vaccine for chickens against Newcastle disease and Marek's disease. The product may be administered in ovo or by subcutaneous injection at hatch, delivering protection against both diseases with one dose. For hatcheries, that timing is central: a prevention decision can be embedded at the beginning of the production cycle rather than added as a later on-farm intervention.

Newcastle disease remains a notifiable disease under EU animal-health rules and can cause mortality and production losses in commercial flocks. Zoetis pointed to recent confirmed outbreaks in Germany, Spain and Poland. Marek's disease is a separate, longstanding flock-health concern, so the dual indication is not merely a label expansion; it offers a way to simplify an early-life protection strategy around two distinct risks.

The immediate commercial effect is choice. Poulvac Procerta HVT-ND joins two related vaccines already authorised by the European Commission: HVT-IBD, for infectious bursal disease and Marek's disease, and HVT-IBD-ND, authorised in 2025 for Newcastle disease, infectious bursal disease and Marek's disease. The resulting portfolio gives veterinarians and producers options to match a programme to local disease pressure and flock objectives, rather than treating every production system as identical.

There is also a trade dimension. Zoetis says the EU approval can unlock export opportunities for producers in southeast Asian countries where the vaccine is already approved. That claim should be read as a market-access opportunity, not a guarantee: export eligibility depends on destination rules, certification and the disease status of the exporting system. Yet it illustrates why regulatory alignment matters in poultry. A vaccine approval in one market can affect the practical choices available to an integrated producer serving another.

For the sector, the larger signal is that hatchery vaccination is becoming a platform decision. A one-dose solution may reduce operational complexity, but its strategic value lies in how it supports disease prevention, programme flexibility and the confidence of commercial partners. In an industry where a health event can quickly become a production and trade event, early-cycle tools that fit both veterinary and market requirements are likely to command increasing attention.

For more information: Zoetis